MannKind registers Phase 2 trial of inhaled nintedanib for pulmonary fibrosis
MannKind Corporation is recruiting patients for a Phase 2 study of MNKD-201, an inhaled dry powder version of nintedanib, in idiopathic pulmonary fibrosis.
MannKind Corporation had one clinical trial update posted this week.
- MannKind's Phase 2 trial of MNKD-201 (Nintedanib Dry Powder Inhalation), called "INFLO-2," is recruiting patients with idiopathic pulmonary fibrosis. The study evaluates the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF)1, with an estimated enrollment of 153 participants and a primary completion date estimated for December 30, 2027. The trial design has participants randomized to receive either 2 mg BID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.